Načítá se...

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially overcome resistance in bortezomib-refractory patients and has significant efficacy in bortezomib-naïve pat...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Fostier, Karel, De Becker, Ann, Schots, Rik
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3463411/
https://ncbi.nlm.nih.gov/pubmed/23055749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S28911
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!